Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercialstage bioelectronic medicine company and wellness company, today announced second quarter 2024 financial results. Recent Highlights • Net loss of $2.7 million, a decrease of 46% over second quarter 2023 • Launched our direct- ...

ROCKAWAY, N.J., Aug. 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2024, Stephen Smith joined electroCore as the Company's VP, Quality, Regulatory, and Compliance, and the Compensation Committee of electroCore's Board of Directors granted 10,000 restricted stock units ("RSUs") to Mr. Smith in connection with the commencement of his employment. The RSUs were granted as an induce ...

Group 1 - electroCore, Inc. announced the appointment of Stephen Smith as VP of Quality, Regulatory, and Compliance on August 1, 2024 [1] - The Compensation Committee granted 10,000 restricted stock units (RSUs) to Mr. Smith as an inducement for his employment, in accordance with NASDAQ Listing Rule 5635(c)(4) [1] - The RSUs will vest in three equal parts over three years, contingent upon Mr. Smith's continued employment [1] Group 2 - electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation (nVNS) technology [2] - The company aims to commercialize medical devices for managing and treating specific medical conditions, as well as consumer products that utilize nVNS for general wellbeing and human performance [2]

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercialstage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. Key benefits of TAC-STIM include: TAC-STIM is available for wholesale purchase only. More informa ...

ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, accord ...

ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to an institutional accredited investor an aggregate of 225,000 registered pre-funded warrants to purchase shares of common stock and unregistered warrants to purchase up to an aggregate of 112,500 shares of common stock. The pre-funded warrants were sold at a purchase price of ...

Shares of electroCore, Inc. (ECOR) have gained 7.8% over the past four weeks to close the last trading session at $6.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.90 indicates a potential upside of 251.8%. The average comprises five short-term price targets ranging from a low of $15 to a high of $29, with a standard deviation of $7.28. While the lowest estimate indicat ...

Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. electroCore, Inc. (ECOR) closed the last trading session at $7.25, gaining 2 ...

electroCore, Inc. (NASDAQ:ECOR) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Bruce Jackson - The Benchmark Company Swayampakula Ramakanth - H.C. Wainwright Nicholas Sherwood - Maxim Group Operator Greetings and welcome to the electroCore First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.61, delivering a surprise of -10.91%.Over the last four quarters, the company has not been ...